Generation of "Virtual" Control Groups for Single Arm Prostate Cancer Adjuvant Trials
文献类型：期刊论文
| 作者 | Jia, Zhenyu1,10,17; Lilly, Michael B.2; Koziol, James A.3; Chen, Xin4; Xia, Xiao-Qin5; Wang, Yipeng6; Skarecky, Douglas7; Sutton, Manuel4; Sawyers, Anne4; Ruckle, Herbert8 |
| 刊名 | PLOS ONE
 |
| 出版日期 | 2014-01-21 |
| 卷号 | 9期号:1页码:e85010 |
| ISSN号 | 1932-6203 |
| 关键词 | RADICAL PROSTATECTOMY POSTOPERATIVE NOMOGRAMS PREOPERATIVE NOMOGRAM 10-YEAR PROBABILITY DISEASE RECURRENCE CLINICAL-TRIAL FOLLOW-UP HIGH-RISK DOCETAXEL EFFICACY |
| 通讯作者 | Jia, ZY (reprint author), Univ Akron, Dept Stat, Akron, OH 44325 USA. |
| 中文摘要 | It is difficult to construct a control group for trials of adjuvant therapy (Rx) of prostate cancer after radical prostatectomy (RP) due to ethical issues and patient acceptance. We utilized 8 curve-fitting models to estimate the time to 60%, 65%, ... 95% chance of progression free survival (PFS) based on the data derived from Kattan post-RP nomogram. The 8 models were systematically applied to a training set of 153 post-RP cases without adjuvant Rx to develop 8 subsets of cases (reference case sets) whose observed PFS times were most accurately predicted by each model. To prepare a virtual control group for a single-arm adjuvant Rx trial, we first select the optimal model for the trial cases based on the minimum weighted Euclidean distance between the trial case set and the reference case set in terms of clinical features, and then compare the virtual PFS times calculated by the optimum model with the observed PFSs of the trial cases by the logrank test. The method was validated using an independent dataset of 155 post-RP patients without adjuvant Rx. We then applied the method to patients on a Phase II trial of adjuvant chemo-hormonal Rx post RP, which indicated that the adjuvant Rx is highly effective in prolonging PFS after RP in patients at high risk for prostate cancer recurrence. The method can accurately generate control groups for single-arm, post-RP adjuvant Rx trials for prostate cancer, facilitating development of new therapeutic strategies. |
| 英文摘要 | It is difficult to construct a control group for trials of adjuvant therapy (Rx) of prostate cancer after radical prostatectomy (RP) due to ethical issues and patient acceptance. We utilized 8 curve-fitting models to estimate the time to 60%, 65%, ... 95% chance of progression free survival (PFS) based on the data derived from Kattan post-RP nomogram. The 8 models were systematically applied to a training set of 153 post-RP cases without adjuvant Rx to develop 8 subsets of cases (reference case sets) whose observed PFS times were most accurately predicted by each model. To prepare a virtual control group for a single-arm adjuvant Rx trial, we first select the optimal model for the trial cases based on the minimum weighted Euclidean distance between the trial case set and the reference case set in terms of clinical features, and then compare the virtual PFS times calculated by the optimum model with the observed PFSs of the trial cases by the logrank test. The method was validated using an independent dataset of 155 post-RP patients without adjuvant Rx. We then applied the method to patients on a Phase II trial of adjuvant chemo-hormonal Rx post RP, which indicated that the adjuvant Rx is highly effective in prolonging PFS after RP in patients at high risk for prostate cancer recurrence. The method can accurately generate control groups for single-arm, post-RP adjuvant Rx trials for prostate cancer, facilitating development of new therapeutic strategies. |
| WOS标题词 | Science & Technology |
| 类目[WOS] | Multidisciplinary Sciences |
| 研究领域[WOS] | Science & Technology - Other Topics |
| 关键词[WOS] | LOCALLY WEIGHTED REGRESSION ; RADICAL PROSTATECTOMY ; POSTOPERATIVE NOMOGRAMS ; SMOOTHING SCATTERPLOTS ; PREOPERATIVE NOMOGRAM ; 10-YEAR PROBABILITY ; DISEASE RECURRENCE ; CLINICAL-TRIAL ; FOLLOW-UP ; HIGH-RISK |
| 资助信息 | United States National Institutes of Health [NCI UO1CA11480, NCI UO1CA152738]; University of California Irvine Faculty Career Development Award; University of California Chao Family Comprehensive Cancer Center Seed Grant; National Cancer Institute [P30CA062203]; CDMRP [W81XWH-08-1-0720] |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000330244500028 |
| 公开日期 | 2014-08-13 |
| 源URL | [http://ir.ihb.ac.cn/handle/342005/20098]  |
| 专题 | 水生生物研究所_水生生物分子与细胞生物学研究中心_期刊论文 |
| 作者单位 | 1.Univ Akron, Dept Stat, Akron, OH 44325 USA 2.Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA 3.Ashford Univ, Coll Hlth Human Serv & Sci, San Diego, CA 92128 USA 4.Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA 5.Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China 6.AltheaDx Inc, San Diego, CA USA 7.Univ Calif Irvine, Dept Urol, Irvine, CA USA 8.Loma Linda Univ, Dept Urol, Loma Linda, CA 92350 USA 9.Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA 10.Guizhou Normal Coll, Guizhou Prov Key Lab Computat Nanomat Sci, Guiyang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Jia, Zhenyu,Lilly, Michael B.,Koziol, James A.,et al. Generation of "Virtual" Control Groups for Single Arm Prostate Cancer Adjuvant Trials[J]. PLOS ONE,2014,9(1):e85010. |
| APA | Jia, Zhenyu.,Lilly, Michael B..,Koziol, James A..,Chen, Xin.,Xia, Xiao-Qin.,...&Mercola, Dan.(2014).Generation of "Virtual" Control Groups for Single Arm Prostate Cancer Adjuvant Trials.PLOS ONE,9(1),e85010. |
| MLA | Jia, Zhenyu,et al."Generation of "Virtual" Control Groups for Single Arm Prostate Cancer Adjuvant Trials".PLOS ONE 9.1(2014):e85010. |
入库方式： OAI收割
来源：水生生物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。